RxDoctor Payments Data

Ann Chen, PA

Physician Assistant · Prince Frederick, MDNPI 1750358438

Payments from drug & device makers

$3,156in general payments, 2019–2025

Across 171 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$733
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$515
  • Johnson & Johnson$362
  • Ferring Pharmaceuticals Inc.$275
  • Madrigal Pharmaceuticals$189
  • Sanofi$185
  • plus $897 from 20 others

What the payments were for

  • Food & beverage$3,00895%
  • Education$1485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,156 in reported general payments places this provider in the 90th percentile of 2,567 physician assistant providers in Maryland.

See all physician assistant providers in Maryland

Medicare billing

Part B allowed, 2024
$67,640
Medicare patients
252
Services billed
724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase27$104,254
Humira PenAdalimumab11$88,637
XifaxanRifaximin23$77,212
LinzessLinaclotide24$34,294
MotegrityPrucalopride Succinate15$10,794
Dexlansoprazole DrDexlansoprazole15$6,448
Budesonide DrBudesonide14$4,523
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates49$2,754
Omeprazole126$2,705
Sucralfate19$1,263
Esomeprazole Magnesium24$1,241
Colestipol Hcl12$1,125
Famotidine87$1,122
Pantoprazole Sodium41$613
Dicyclomine Hcl28$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$733$138,54951 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$515$77,21223 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$12$10,79415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,567 physician assistant providers in Maryland.

Other physician assistant in Prince Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →